Endocrinology and hormone therapy in breast cancer: Selective oestrogen receptor modulators and downregulators for breast cancer – have they lost their way?

Table 3 Clinical efficacy of idoxifene versus tamoxifen

Shown is a summary of efficacy data from two randomized double-blind phase III trials of idoxifene (40 mg/day) versus tamoxifen (20 mg/day) as first-line therapy in advanced/metasatic breast cancer. CBR, percentage of patients with either objective response or stable disease for 6 months or longer; ORR, percentage of patients with an objective response, including complete response and partial response; TTP, median time to disease progression.

ISSN: 1465-542X